00:00 / 00:00
ANTIBIOTICS: CARBAPENEMS AND MONOBACTAMS | ||
DRUG NAME | doripenem, ertapenem (INVanz), meropenem, meropenem-vaborbactam (Vabomere), imipenem–cilastatin (Primaxin IV) | aztreonam (Azactam, Cayston) |
CLASS | Carbapenem; beta-lactam antibiotic | Monobactam; beta-lactam antibiotic |
MECHANISM of ACTION | Bind to the PBPs of gram-negative bacteria and inhibit cell wall formation, eventually eliminating the bacteria | |
INDICATIONS |
|
|
ROUTE(S) of ADMINISTRATION |
|
|
SIDE EFFECTS |
|
|
CONTRAINDICATIONS & CAUTIONS | Contraindications:
Precautions:
Drug interactions:
| Contraindications:
Precautions:
|
NURSING CONSIDERATIONS FOR ANTIBIOTICS: CARBAPENEMS AND MONOBACTAMS | ||
ASSESSMENT AND MONITORING | Assessment and monitoring: imipenem-cilastatin Assessment
| |
CLIENT EDUCATION |
|
Carbapenems and monobactams are beta-lactam antibiotics, which means that they have a characteristic beta-lactam ring in their structure. However, due to their widespread use, some bacteria have acquired resistance to many beta-lactams by developing enzymes called beta-lactamases, which latches on to the beta-lactam ring and degrades the antibiotic. For this reason, carbapenems and monobactams have a slight modification in their beta-lactam ring structure, which makes them less susceptible to beta-lactamases.
Now, carbapenems can be used to treat serious infections, such as complicated appendicitis, peritonitis, soft-tissue infections, bacterial meningitis, as well as gynecological infections, pyelonephritis, and bacteremia. Carbapenems have a wide range of action against gram-positive bacteria like methicillin-sensitive Staphylococcus aureus, Streptococcus pneumoniae, and group A beta-hemolytic streptococci; and gram-negative bacteria like Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella spp, Neisseria spp, and Acinetobacter spp.
On the other hand, monobactams are only useful in the treatment of gram-negative bacterial species, and are primarily used to treat clients with cystic fibrosis who have pulmonary Pseudomonas aeruginosa infections.
Starting with carbapenems, the most commonly used ones include doripenem, ertapenem, meropenem, as well as meropenem-vaborbactam, a combination of meropenem and vaborbactam, a beta-lactamase inhibitor, which further increases the spectrum of activity, and imipenem-cilastatin, a combination of carbapenem and the dipeptidase inhibitor cilastatin which prevents imipenem from being broken down, prolonging its antibacterial effect. Now, all of the carbapenems are administered intravenously, and ertapenem can also be given intramuscularly.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.